The relative merits and drawbacks of new nucleoside analogues with clinical potential

A large number of nucleoside analogues have been found to have antiviral activity, mainly against herpesviruses. The involvement of cellular as well as viral enzymes in the mode of action of several nucleoside analogues makes a prediction of clinical efficacy difficult. The possibility and consequen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1984-01, Vol.14 (suppl-A), p.5-26
Main Authors: Öberg, B., Johansson, N.-G.
Format: Article
Language:English
Subjects:
Acyclovir - analogs & derivatives
Acyclovir - therapeutic use
Animals
Antiviral Agents - metabolism
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral Agents - toxicity
Biotransformation
Bromodeoxyuridine - analogs & derivatives
Bromodeoxyuridine - therapeutic use
Cytarabine - analogs & derivatives
Cytarabine - therapeutic use
DNA-Directed RNA Polymerases - antagonists & inhibitors
Ganciclovir
Humans
Idoxuridine - therapeutic use
Nucleic Acid Synthesis Inhibitors
Nucleic Acids - biosynthesis
Nucleosides - metabolism
Nucleosides - therapeutic use
Ribavirin - therapeutic use
Trifluridine - therapeutic use
Vidarabine - therapeutic use
Viruses - enzymology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A large number of nucleoside analogues have been found to have antiviral activity, mainly against herpesviruses. The involvement of cellular as well as viral enzymes in the mode of action of several nucleoside analogues makes a prediction of clinical efficacy difficult. The possibility and consequences of incorporation into cellular DNA are other important aspects of nucleoside analogues as antiviral drugs. It seems likely that in the next few years enough knowledge about mechanism of action, consequences of incorporation into DNA, efficacy in different test systems and in clinical trials will accumulate to allow an understanding of how to design even better antiviral drugs.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/14.suppl_A.5